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CD47 Inhibits Self-renewal by Regulating
c-Myc and Other Stem Cell Transcription
Factors
Sukhbir Kaur1, David R. Soto-Pantoja1, Erica V. Stein1,2, Chengyu Liu3, Abdel G. Elkahloun4,
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Signaling through the thrombospondin-1 receptor CD47 broadly limits cell and tissue survival of stress, but
the molecular mechanisms are incompletely understood.We now show that loss of CD47 permits sustained
proliferation of primary murine endothelial cells, increases asymmetric division, and enables these cells to
spontaneously reprogram to form multipotent embryoid body-like clusters. c-Myc, Klf4, Oct4, and Sox2
expression is elevated in CD47-null endothelial cells, in several tissues of CD47- and thrombospondin-1-
null mice, and in a human T cell line lacking CD47. CD47 knockdown acutely increases mRNA levels of
c-Myc and other stem cell transcription factors in cells and in vivo, whereas CD47 ligation by
thrombospondin-1 suppresses c-Myc expression. The inhibitory effects of increasing CD47 levels can be
overcome by maintaining c-Myc expression and are absent in cells with dysregulated c-Myc. Thus, CD47
antagonists enable cell self-renewal and reprogramming by overcoming negative regulation of c-Myc and
other stem cell transcription factors.
C
D47 is a signaling receptor for the secreted matricellular protein thrombospondin-1 and the counter-
receptor for signal-regulatory protein-a (SIRPa), which on phagocytic cells recognizes CD47 engagement
as a marker of self1–3. Mice lacking CD47 or thrombospondin-1 are profoundly resistant to tissue stress
associated with ischemia, ischemia/reperfusion, and high dose irradiation2,4–7. The survival advantage of ischemic
CD47- and thrombospondin-1-null tissues is mediated in part by increased nitric oxide/cGMP signaling2.
Radioresistance associated with CD47 blockade is cell autonomous and independent of NO signaling8, indicating
that additional pro-survival signaling pathways are controlled by CD47.
Engaging CD47 in some cell types triggers programmed cell death3,9. BCL2/adenovirus E1B 19 kDa protein-
interacting protein 3 (BNIP3) is a pro-apoptotic BH3 domain protein that interacts with the cytoplasmic tail of
CD47 and is implicated in CD47-dependent cell death10. Furthermore, CD47 ligation alters localization of the
dynamin-related protein Drp1, which controls mitochondria-dependent death pathways9, and some tissues in
CD47-null and thrombospondin-1-null mice show increased mitochondrial numbers and function11.
Mitochondrial-dependent cell death pathways involving Bcl-2 are limited by the autophagy regulator beclin-112.
We recently found that CD47 signaling limits the induction of beclin-1 and other autophagy-related proteins in
irradiated cells, and blocking CD47 in vitro and in vivo thereby increases activation of a protective autophagy
response13,14. This autophagy response is necessary for the radioprotective effect of CD47 blockade.
In contrast to the above noted survival advantages of decreased CD47 expression, elevated expression of CD47
confers an indirect survival advantage in vivo. CD47 engages SIRPa on macrophages and prevents phagocytic
clearance1,15. Similarly, elevated expression of CD47 on several types of cancer cells has been shown to inhibit
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macrophage-dependent clearance of tumors17,19–21, although others
have shown that such clearance can occur independent of inhibitory
SIRPa signaling22–24.
Taken together, these studies indicate two opposing roles for
CD47 in cell survival. The cell autonomous advantages of decreased
CD47 expression, leading to less inhibitory CD47 signaling, must be
balanced against the need to maintain sufficient CD47 levels to pre-
vent phagocytic clearance in vivo. Hematopoietic stem cells exhibit
elevated CD47 expression, and high CD47 expression in the stem cell
niche was proposed to be important to protect stem cells from innate
immune surveillance25. In contrast to this protective function of
CD47 in stem cells, we now report that loss of CD47 elevates express-
ion of the stem cell transcription factors Sox2, Klf4, Oct4, and c-Myc
in primarymurine endothelial cells. Consequently, these cells exhibit
increased asymmetric cell division and spontaneously and efficiently
form clusters that resemble embryoid bodies (EBs) in serum-free
media without requiring feeder cells. These EB-like clusters can
readily differentiate into various lineages. c-Myc is a global regulator
of gene expression in differentiated and stem cells26 and plays amajor
role in this inhibitory function of CD47. Re-expression of CD47 in
null cells down-regulates c-Myc expression and inhibits cell growth,
whereas dysregulation of the c-Myc gene, such as commonly occurs
in cancer, enables cells to tolerate high CD47 expression.
Results
Loss of CD47 allows self-renewal and increases c-Myc expression.
Primary cells isolated from CD47-null mice exhibit a remarkable
advantage in adapting to the stress of tissue culture. Lung endo-
thelial cells isolated from WT C57Bl/6 mice had limited survival and
proliferative capacities in primary culture as assessed by reduction
of [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) and bromodeoxyuri-
dine (BrdU) incorporation (Fig. 1A, B) and rapidly became
senescent upon passage (Supplemental Fig. S1). In contrast,
Figure 1 | Enhanced proliferation and decreased senescence of CD47-null murine endothelial cells is associated with increased expression of c-Myc.
(A) MTS assay for cell survival and growth over 72 h expressed as % of day 0 values at the indicated plating densities of first passage WT and CD47 null
cells. (B) BrdU assay for DNA synthesis. (C) Percentage of senescence-associated b-galactosidase expression at passage 3. (D) Expression of genes
associated with cell immortalization in WT and CD47 null cells. (E) c-Myc mRNA levels in lung endothelial cells of WT and CD47 null mice. (F) CD47
limits c-Myc protein levels. (G) c-Myc expression (red) inWT and CD472/2 endothelial cells. Blue 5 DAPI nuclear stain. (H) Flow cytometric analysis
of c-Myc expression in WT and CD472/2 endothelial cells. (*p , 0.05, **p , 0.01).
www.nature.com/scientificreports
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CD47-null lung endothelial cells at first passage showed
enhanced plating efficiency and proliferation at several cell
densities (Fig. 1A, B). Upon repeated passage, WT primary
cells became flattened and vacuolated, whereas CD47-null
endothelial cells consistently maintained a well differentiated
cobblestone morphology for several months in continuous
culture (Supplemental Fig. S1). Continuously proliferating cell
lines were reproducibly obtained when primary CD47-null
cells were repeatedly passaged but very rarely from WT
cultures. The CD47-null cells generally lacked expression of
the senescence-associated acidic b-galactosidase marker27 that
rapidly appeared in the WT cells (Fig. 1C). High frequency
generation of continuously proliferating cell lines was also
observed for lung endothelial cells cultured from mice lacking
the CD47 ligand thrombospondin-1 (Supplemental Fig. S1).
The ability of CD47-null and thrombospondin-1-null cells to
continuously proliferate could reflect either increased escape from
senescence or induction of a self-renewing stem cell phenotype.
Genes that enable primary cells to escape senescence and become
immortalized include p53, Rb, p16-INK4A, and c-Myc28. Of these,
only c-Myc mRNA levels were significantly elevated relative to
HPRT1 mRNA levels in the primary cell cultures and remained
elevated upon repeated passage (Fig. 1D, E). Protein levels for c-
Myc were also elevated in primary CD47-null lung endothelial cells
as detected by western blotting (Fig. 1F, 2C), immunofluorescence
(Fig. 1G) and flow cytometry (Fig. 1H). Most c-Myc was nuclear, but
filamentous cytoplasmic staining was also noted in the CD47-null
cells, consistent with the known c-Myc association with microtu-
bules29. Characteristic of a pure endothelial cell culture30, the con-
tinuously growing CD47-null cells uniformly expressed VEGFR2
and heterogeneously expressed CD31 (Fig. 2D). Absence of vascular
smooth muscle cell contamination was indicated by the lack of
detectable a-smooth muscle actin expression, although this was
detectable at low levels in primary WT endothelial cell cultures
(Fig. 2C).
CD47 coordinately regulates stem cell transcription factors.
Because elevated c-Myc expression also promotes self-renewal of
Figure 2 | Stem cell and differentiation marker expression in WT and CD47-null endothelial cells. (A) mRNA expression levels of stem cell
transcription factors inWT and CD47 null lung endothelial cells. (B, D) Stem cell and differentiation marker expression inWT (B) and CD47 null mouse
endothelial cells (D). The endothelial cells were stained using the indicated antibodies andDAPI (blue). Scale bars5 5 mm. (C) Protein expression of stem
cell transcription factors and smooth muscle actin (SMA) assessed by western blotting and flow cytometry (Oct4) in cultured WT or CD47 null
endothelial cells in EGM2 medium. (E) Asymmetric cell division frequencies in second passage WT and CD472/2 endothelial cells equilibrium labeled
with BrdU and chased for one cell division. Asymmetric division was scored by counting BrdU1(green)/DAPI1 nuclei adjacent to BrdU2/DAPI1 nuclei.
www.nature.com/scientificreports
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stem cells31 and is necessary under some conditions for embryonic
stem cell self-renewal32, we examined the expression of additional
transcription factors that support stem cell reprogramming33 and
found significant elevation of mRNA for Sox2, Klf4, and Oct4 and
of the stem cell marker nestin in primary CD47-null endothelial cells
(Fig. 2A). Oct4 protein expression was detected by immuno-
fluorescence in a majority of the CD47 null cells but not in WT
cells (Fig. 2B, D). Sox2 and Klf4 were expressed in a subset of
CD47-null cells, whereas Klf4 and c-Myc were undetectable by
immunofluorescence in WT endothelial cells, and Sox2 positive
cells were rarely seen (Fig. 2B, D). Some Sox2 staining in CD47
null cells was cytoplasmic, consistent with its reported subcellular
localization in early embryonic cells34, but the majority of staining
was nuclear. Western blotting confirmed elevated levels of Klf4 and
Oct4 in CD47-null versus WT cells (Fig. 2C). Flow cytometry also
confirmed increased Oct4 expression in CD47-null cells (Fig. 2C).
These data suggested that CD47-null endothelial cell cultures con-
tain a larger fraction of stem cells, which characteristically exhibit
asymmetric cell division35,36. We examined the frequency of asym-
metric division in WT and CD47-null endothelial cell cultures uni-
formly labeled using BrdU by chasing with unlabeled medium for
24 h in the presence of cytochalasin B to inhibit cytokinesis.
Asymmetric division was indicated by adjacent DAPI1 nuclei where
only one cell retained BrdU staining (Fig. 2E upper panel). Such cells
were significantly more abundant in the CD47-null cultures (Fig. 2E
lower panel).
Efficient formation of embryoid body-like clusters by CD47-null
cells. Ectopic expression of Klf4, Sox2, Oct4, and c-Myc or ALK2
bearing an activating mutation in human umbilical vein endothelial
cells enables efficiently generation of multipotent or induced
pluripotent stem (iPS) cells37,38, suggesting that self-renewal of the
CD47-null endothelial cells might arise from increased numbers of
stem cells in these cultures. Continuously propagated CD47-null
endothelial cells expressed Sca-1, and 24% of the cells were
CD141/CD111 (Fig. S1). These are characteristic markers for
endothelial precursor cells39. However, CD47-null endothelial cells
did not express detectable levels of pluripotency marker SSEA-1 or
the stem cell marker c-Kit (Fig. 2D). Because elevated expression of
c-Myc, Sox2, Oct4 and Klf4 in some types of primary cells is
sufficient to induce cystic EB formation40, we examined whether
loss of CD47 circumvents the need to artificially elevate these
factors for inducing EBs. Indeed, transfer of early passage CD47-
null endothelial cells, as well as cultures grown continuously for up
to 6 months, into serum-free medium in the absence of any feeder
cells within 2 days induced efficient formation of floating cell
aggregates that resembled EBs and continued to proliferate in this
state (Fig. 3A, Supplemental Fig. S2). These were never observed
when primary WT endothelial cells were placed into the same
medium, and WT cells did not survive in serum-free media. Cells
in the EB-like clusters exhibited strong nuclear c-Myc staining by
immunofluorescence (Fig. 3A) and flow cytometry indicated a
subpopulation with stronger c-Myc expression than that observed
in primary CD47-null endothelial cultures (compare Fig. 3B and
Fig. 1H). Unlike CD47-null cells in endothelial cell medium, cells
in the EB-like clusters expressed additional stem cell markers
including alkaline phosphatase, nestin, SSEA-1 and c-Kit (Fig. 3A,
S4). Consistent with their expression of stem cellmarkers, cells in EB-
like clusters frequently exhibited asymmetric cell division (Fig. 3C).
CD472/2 cells were grown without feeder cells in ES medium
containing LIF adopted colony morphologies similar to V6.5 mouse
ES cells grown in the same medium with MEF feeder cells (Fig. 3D).
Immunohistochemical analysis of these cells in ES medium demon-
strated that CD47 null and V6.5 ES cells contained similar subpo-
pulations that expressed elevated levels of nuclear Oct 4, Sox2, and
Nanog (Fig. 3E).
We performed microarray analyses (GSE43133) to globally assess
the stem cell character of CD47 null endothelial cells and EB-like
clusters derived by culturing in serum freemedium for 36 h. A global
principal component analysis revealed that CD47 null endothelial
cells and EB-like clusters derived from them clustered near published
iPS and ES cells, whereas WT endothelial cells did not (Fig. 3F). To
characterize the changes in gene expression that accompany EB-like
cluster formation in the CD47 null cells, we compared global
gene expression in CD47 null EB-like clusters to that of CD47 null
cells before removal of serum and endothelial growth factors and
found 383 genes with significant changes. Of these 255 clustered with
genes that showed similar up or down regulation in the V6.5 ES cells
(Supplemental Fig. S3). A GeneSet gene enrichment analysis (GSEA)
identified 39 of these up-regulated genes that are included in the
molecular signature for human ES cells defined by Bhattacharya41
(Supplemental Fig. S3). The remaining genes included endothelial-
specific genes that were significantly down-regulated (e.g. thrombo-
modulin (Thbd)) and epithelial/mesenchymal transition genes that
were induced when CD47 null cells formed EB-like clusters. Notably
expression of Kdr, which encodes VEGFR2, decreased 10-fold, con-
sistent with loss of VEGFR2 immunoreactivity in the CD47 null EB-
like clusters.
CD47-null EB-like clusters are multipotent. To determine whether
CD47 null EB-like clusters are competent to give rise to the three
germ layers, 6 day old undifferentiated EB-like clusters prepared
from continuously cultured CD47-null endothelial cells were
plated on gelatin-coated WillCo dishes for 36 h containing neural,
smooth muscle, or hepatocyte differentiation medium (Fig. 4A–C
and Movies S1–3). Appearance of cells expressing smooth muscle
actin indicated mesoderm differentiation. Cells expressing neuron-
specific b III tubulin and glial fibrillary acidic protein (GFAP)
indicated ectoderm differentiation. Cells expressing a-fetoprotein
(AFP) indicted endoderm differentiation. Because each lineage
could arise from different lineage-committed stem cells in the EB-
like clusters, we expanded a single clone from CD47-null EB-like
clusters and repeated the above differentiation study (Fig. 4D–F).
Again, cells expressing characteristic markers of the three
embryonic lineages were obtained. Therefore, the CD47-null cells
are multipotent.
Morphological differentiation of EBs provides another in vitro
assessment of pluripotency42. Differentiation of EB-like clusters in
complete RPMI medium for 10–15 days resulted in morphological
differentiation characteristic of all three embryonic germ layers
(Supplemental Fig. S5). Differentiation was accompanied by loss
of SSEA1 expression and decreased expression of other stem cell
markers.
These results suggested that CD47 null EB-like clusters contain
pluripotent cells. However, we observed limited fibrotic responses
and no teratoma formation when CD47 null EB-like clusters were
injected into NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice under
conditions where v6.5 ES cells formed teratomas. Therefore, the
CD47-null EB-like clusters are probably not fully pluripotent43.
Alternatively, teratoma formation may have been prevented by
SIRP-dependent clearance of the CD47 null cells15.
Further evidence for multipotency was obtained when undiffer-
entiated CD47-null EB-like clusters were dispersed and cultured in
neural medium on a gelatin coated substrate (Supplemental Fig. S6).
Ectodermal differentiation was indicated by expression of the neur-
onal markersMAP2, GFAP, neuron-specific beta III tubulin, and the
astrocyte marker S100b respectively (panels d–h). Some nonadher-
ent colonies formed from these cells exhibited extensive neurite
formation (panels a–c).
CD47 null endothelial cells cultured in hepatocyte growth med-
ium developed into cystic EB-like clusters and then differentiated
into cells that expressed the hepatocyte marker a-fetoprotein
www.nature.com/scientificreports
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(AFP, Supplemental Fig. S6). The CD47-null endothelial cells from
which these were derived did not express AFP. Although, a few WT
endothelial cells survived in the hepatocyte medium, EB-like clusters
never formed, and no expression of AFP was observed.
WT and CD47 null endothelial cells were cultured in mesenchy-
mal cell medium for 10 days. Only CD47 null cells formed EB-like
clusters. Some colonies of the mesenchymal differentiated cells
exhibited oil red O1 lipid vacuoles characteristic of adipocytes
(Supplemental Fig. S6). Dispersion of CD47-null EB-like clusters
into serum-free smooth muscle medium containing platelet-derived
growth factor and transforming growth factor-b1 resulted in differ-
entiation of cells with typical vascular smooth muscle morphology
and expressing the lineage marker smooth muscle actin (Supple-
mental Fig. S6).
Hematopoietic differentiation of CD47 null endothelial cells. To
determine their potential to differentiate into a myeloid lineage,
CD47-null endothelial cells were cultured with L929 conditioned
medium as a source of macrophage colony stimulating factor (M-
CSF)44. After 10 days a change in cell morphology was accompanied
by a marked increase in the percentage of Mac21 cells in treated
CD47-null cells compared to the same cells in endothelial growth
medium and loss of Sca-1 expression (compare Supplemental
Figs. S1 and S7).
In vivo regulation of c-Myc and tissue stem cell abundance by
CD47. Increased expression of c-Myc mRNA compared to that in
WT mice was detected in several organs from CD47-null mice
(Fig. 5A). Because the highest elevation occurred in CD47-null
Figure 3 | Stem cell marker expression in CD47 null EB-like clusters. (A) Top left: Typical appearance of EB-like clusters photographed under phase
contrast. Top right: Staining with c-Myc antibody (red) and DAPI (blue). Bottom panels: EB-like clusters or cells dissociated from themwere stained using
the indicated antibodies (green) and DAPI (blue). Scale bars5 5 mm. (B) Flow cytometric analysis of c-Myc expression in CD47-null cells dissociated from
EB-like clusters. (C) Detection of asymmetric cell division in cells from CD47-null EB-like clusters equilibrium labeled with BrdU and then chased for two
cell divisions without BrdU and stained with anti-BrdU (red) and phalloidin to visualize actin (green). Blue 5 DAPI. (D) Morphologies of CD47 null
EB-like clusters and V6.5 ES cells growing in ES medium with LIF. The V6.5 culture also contains a MEF feeder layer. (E) CD47 null EB-like clusters and
V6.5 ES cells cultured as in D and CD47 null endothelial cells in endothelial growth medium (right panels) were stained using the indicated antibodies
(magenta) and DAPI (blue). Scale bars 5 5 mm. (F) Principal component analysis of global gene expression data for WT (purple) and CD47 null
endothelial cells (red), and CD47 null EB-like clusters (blue) compared with published expression data for iPS (gold) and ES cells (green).
www.nature.com/scientificreports
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spleen, we examined several major cell types from this organ. B
(CD191) and CD41 T cell populations showed significant up-
regulation of c-Myc mRNA, whereas CD81 T cells and monocytes
did not (Fig. 5B). Nestin, Sox2, KLF4, and Oct4 mRNA levels were
also markedly elevated in spleen from CD47-null mice (Fig. 5C).
Consistent with the lesser elevation of c-Myc mRNA levels in lung,
Oct4, Sox2, and nestin mRNA levels were moderately elevated in
lung, but KLF4 was not elevated in this organ (Fig. 5D). Sox2 is
normally expressed by Clara cells in conducting airways45 and was
similarly expressed in WT and CD47-null lung bronchiolar
epithelium, but cells expressing higher levels of cytoplasmic Sox2
were selectively observed throughout the alveolar space of the
CD47-null lung (Fig. 5E–F).
The spleen of adult mice contains a pool of multipotent CD452/
Hox111 stem cells that reside in the sub-capsular red pulp and are
capable of differentiating into diverse lineages46,47. Consistent with
these reports, we observed a limited number of cells with nuclear
Sox2 protein expression in the sub-capsular region of WT mouse
spleen (Fig. 5G) and sparse expression of Sox2-expressing cells in
other compartments of the spleen. Similar subcapsular Sox2
immunoreactivity was seen in spleen sections from CD472/2 mice,
but more extensive staining was observed in the adjacent red pulp
(Fig. 5H, Supplemental Fig. S7). These differences in Sox2 protein
expression are consistent with the whole organ mRNA expression
data and suggest that the absence of CD47 increases the number of
tissue resident stem cells in vivo.
CD47 expression acutely inhibits c-Myc expression. The above
results establish a genetic linkage between CD47, maintenance of
stem cells, and c-Myc expression but do not prove that CD47
signaling directly controls expression of c-Myc or the other stem
cell transcription factors. To clarify this relationship, WT splenic
T cells from c-Myc-EGFP knock-in mice26 were treated with a
previously validated CD47-targeting antisense morpholino48 and
resulted in a 7-fold increase in c-Myc mRNA level at 24 h
(Fig. 6A). Intraperitoneal injection of the CD47 morpholino into
WT mice significantly decreased CD47 protein expression in vivo
(Supplemental Fig. S8) and resulted in induction of c-Myc as well
Oct4 and Sox2mRNA levels in spleen at 48 h (Fig. 6B). These results
are consistent with our previous report that intraperitoneal injection
of this CD47 morpholino confers radioprotection to mice8.
Conversely, re-expression of CD47 in CD47-null endothelial cells
by transiently transfecting a human CD47 expression plasmid inhib-
ited their proliferation and viability (Fig. 6C). c-Myc mRNA and
protein levels fell when CD47 was re-expressed at a level sufficient
to cause growth inhibition (Fig. 6D–E, Supplemental Fig. S8).
Growth suppression by transiently expressing CD47 could be par-
tially overcome by co-transfecting the cells with a c-Myc expression
vector (Fig. 6C). Transient re-expression of CD47 in the null
endothelial cells also decreased mRNA levels for KLF4, Sox2, and
nestin (Fig. 6F). Notably, over-expressing c-Myc alone increased
nestin and Oct4 mRNA expression, but co-expression of c-Myc with
CD47 did not overcome the inhibitory effect of CD47 expression on
KLF4, Sox2, or nestin, indicating that these CD47 signaling targets
are Myc-independent.
Thrombospondin-1 controls c-Myc via CD47. The JinB8 somatic
mutant of the Jurkat human T lymphoma cell line lacks CD4749 and
Figure 4 | Differentiation of CD47-null EB-like clusters. (A) EB-like clusters were cultured in the presence of serum for 6 days to induce substrate
adhesion and then transferred in to the indicated lineage specific media for 36 h and stained with smooth muscle actin antibody (red) to detect
mesodermal cells. (B) Differentiated EB-like clusters were stained with the ectoderm neural markers glial fibrillary acidic protein (GFAP, green), neuron-
specific beta III tubulin (TUJI, red). (C) Differentiated EB-like clusters were stained with anti-a-fetoprotein (red) to detect ectodermal cells. In all panels
DAPI was used to visualize nuclei (blue). (D–F) A single clone isolated from a CD47-null EB-like cluster in serum-free medium was expanded and then
differentiated in the indicated lineage-specific medium for 7 days and stained for the indicated markers. Blue 5 DAPI, green in (F) 5 actin.
www.nature.com/scientificreports
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exhibited a similar over-expression of c-Myc mRNA relative to the
parental Jurkat cells (Fig. 7A). Therefore, CD47 also negatively
regulates c-Myc expression in human cells. Mice lacking the CD47
ligand thrombospondin-1 share most of the stress resistance
phenotypes of CD47 null mice2,7, and muscle explants from
thrombospondin-1-null mice exhibit increased vascular outgrowth
into 3-dimensional collagen gels relative to WT explants50.
Consistent with these observations and the continuous growth of
thrombospondin-1-null endothelial cells, c-Myc levels in Jurkat T
cells were transiently induced but then strongly inhibited by
treatment with 2.2 nM thrombospondin-1 (Fig. 7B). Picomolar
concentrations of thrombospondin-1 were sufficient to inhibit c-
Myc expression in Jurkat cells at 24 h, but the elevated c-Myc
mRNA levels in Jurkat cells lacking CD47 were not significantly
inhibited by thrombospondin-1 (Fig. 7C). Re-expression of CD47
in JinB8 cells reduced c-Myc mRNA expression (Fig. 7D) and
restored the ability of thrombospondin-1 to inhibit c-Myc
expression (Supplemental Fig. S8). Therefore, CD47 is necessary
for this activity of thrombospondin-1. The transient induction of
c-Myc by thrombospondin-1 may be mediated by its other
receptors expressed by Jurkat cells51.
Similar suppression of c-Myc levels was observed in the presence
of a CD47-binding peptide derived from thrombospondin-1 (pep-
tide 7N3, Fig. 7E). A control peptide with a mutated CD47 binding
motif (peptide 604) was inactive. Therefore, CD47 engagement is
sufficient to inhibit c-Myc expression without the participation of
other thrombospondin-1 receptors.
Endogenous thrombospondin-1 also controls expression of c-Myc
mRNA in vivo (Fig. 7F, G). c-Myc mRNA levels were elevated
approximately 3-fold in thrombospondin-1-null spleen and lung
tissues relative to the corresponding WT organs. Consistent with
the data for CD47-null mice, Oct4, Sox2 and KLF4 mRNA levels
were also elevated in thrombospondin-1-null spleen, but their levels
were not significantly increased in lung.
Dysregulation of c-Myc confers resistance to CD47 signaling.One
paradox that arises from the above results is that high CD47
expression appears to be a disadvantage for cells because it
suppresses c-Myc expression, yet many tumor cells and some stem
cells have elevated CD47 expression17,19–21. One possible explanation
is that other pathways that drive cMyc expression could overcome
the inhibitory effects of CD47 signaling. To examine whether c-Myc
is the primary target of CD47 signaling that inhibits cell growth, we
usedMyc-null rat1 fibroblasts that constitutively express a tamoxifen
activatable c-Myc-estrogen receptor chimeric protein52. In contrast
to cells expressing only native c-Myc controlled by its endogenous
promoter, transfecting the Myc-expressing Rat1 fibroblasts with
CD47 did not inhibit their growth (Fig. 7H).
We previously reported that blocking CD47 conferred radiopro-
tection to normal cells and mice, but B16 melanomas grown in these
mice were not protected and instead showed enhanced radiosensi-
tivity when CD47 was blocked8. This, combined with previous evid-
ence that c-Myc expression is dysregulated in B16 cells53, suggested
that CD47 signaling might not regulate c-Myc in these cells.
Consistent with this hypothesis, transiently over-expressing CD47
in B16 melanoma cells did not inhibit their growth (Fig. 7H).
Over-expression of CD47 also failed to inhibit growth or survival
of Raji Burkitt’s lymphoma cells where c-Myc expression is driven by
enhancer regions donated by the translocated immunoglobulin
heavy chain54 (Fig. 7I). In agreement with these growth data, cell
Figure 5 | Loss of CD47 is associated with up-regulation of stem cell transcription factors in vivo. (A) Relative c-MycmRNA expression in lung, kidney,
liver, brain and spleen of CD47-null versus WT mice. (B) c-Myc mRNA levels in purified splenic cell populations from WT and CD47 null mice.
(C) mRNA expression levels in lung from WT and CD47-null mice. (D) mRNA expression levels in spleen from WT and CD47-null mice. (*p, 0.05,
**p, 0.01). (E–H) Increased frequency of Sox2 expressing cells in tissues from CD47-null mice. The alveolar (Alv) regions of lung tissues fromWT (E)
generally lack Sox2-positive cells (brown stain), whereas CD47-null lung shows more positive cells (F). In contrast, similar uniform Sox2 staining was
observed in bronchiolar epithelium (BrEp) from WT and null mice, consistent with its previously reported expression in Clara cells45. (G–H) Paraffin
embedded sections of representative spleen tissues from WT (G) and CD472/2 (H) mice were stained with a specific antibody to Sox2. Sections were
examined under light microscopy showing subcapsular (CP), red pulp (RP) and white pulp (WP) staining.
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cytoxicity (LDH release) was increased by re-expressing or over
expressing CD47-FLAG in normal mouse lung endothelial cells
but not in B16 melanoma, Raji Burkitt’s lymphoma, and Myc null
Rat 1 fibroblasts (Supplemental Fig. S8). Together, these results
establish that c-Myc is the dominant target of CD47 signaling for
limiting cell growth and suggest that this regulation requires 59-
regions of the c-Myc gene, which are absent in Raji cells.
Discussion
These results demonstrate that a population ofmultipotent stem cells
is selectively maintained at high frequency in primary and continu-
ously cultured CD47-null endothelial cells. These cells support long
term maintenance of viable endothelial cells in medium containing
endothelial growth factors, but when deprived of serum CD47-null
cells spontaneously generate EB-like clusters that express pluripo-
tency markers including alkaline phosphatase, Nanog, and SSEA-1.
These in turn can be induced to differentiate into cell types repres-
entative of all three embryonic germ layers when appropriate growth
factors and cytokines are provided. In contrast to exhibiting these
characteristics of iPS cells, the CD47 null EB-like clusters did not
form teratomas. Consistent with their lack of teratoma formation, we
found no loss of expression of the tumor suppressor gene PTEN or
activation of oncogenes including Ras in CD47-null EB-like clusters.
Loss of PTEN was reported to increase teratoma formation by plur-
ipotent stem cells55. Others have shown that stem cells can remain
pluripotent when teratoma formation is suppressed56. Thus, the
CD47-null EB-like clusters may not be fully pluripotent, but their
lack of tumorigenicity would be an advantage for potential thera-
peutic applications57.
Our data reveal that suppression of c-Myc expression is an import-
ant mechanism by which thrombospondin-1 signaling via CD47 con-
trols cell growth and differentiation. c-Myc is now recognized to be a
universal amplifier of the expression of actively transcribed genes in
somatic and embryonic stem cells26, so the ability of CD47 to control
c-Myc expression identifies CD47 as cell surface receptor that globally
regulates gene expression. Combined with its specific regulation of
the stem cell transcription factors Oct4, Sox2 and Klf4, CD47 limits
the growth, self-renewal, and reprogramming capacity of primary
murine cells in tissue culture. Suppression of these major stem cell
transcription factors by CD47 also occurs in vivo and can be modu-
lated by targeting CD47. A corresponding increase in the abun-
dance of tissue stem cells, suggested by the increased numbers of
Figure 6 | CD47 expression regulates c-Myc and stem cell transcription factor expression. (A) Morpholino knockdown of CD47 in lung endothelial
cells increases c-Myc mRNA expression. (B) In vivo morpholino knockdown of CD47 elevates c-Myc, Oct4, and Sox2 mRNA at 48 h in mouse spleen.
(C) CD47 re-expression in CD47-null murine endothelial cells suppresses cell growth unless c-Myc expression is sustained. (D) CD47 re-expression in
CD47 null endothelial cells alters expression c-Myc compared withWT (E) Expression level of transfected human CD47. (F) Re-expression of CD47 and
c-Myc alters mRNA expression of stem cell transcription factors. (*p , 0.05, **p , 0.01).
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Sox2-positive cells in several organs of CD47-null mice, may contrib-
ute to the remarkable ability of tissues in these mice and in throm-
bospondin-1 null mice to recover from various injuries2,58. In addition
to the potential therapeutic utility of CD47 antagonists for treating
such injuries, the present data suggest that antagonists of CD47 sig-
naling could be used to increase the ex vivo expansion of tissue stem
cells for cell-based therapies and tissue engineering. We propose that
CD47 antagonists may also be useful to enhance the generation of
lineage-committed or multipotent stem cells and to circumvent the
requirement for ectopic expression using plasmids or integrating
retroviruses encoding tumor promoting genes such as c-Myc.
c-Myc expression greatly increases the frequency of iPS cells
induced by combined ectopic expression of Oct3/4, Sox2, and
Klf432. Because our data show that CD47 limits c-Myc expression
and other studies have shown that thrombospondin-1 inhibits
endothelial progenitor cell function via CD4759, it is remarkable that
CD47 expression is elevated on hematopoietic stem cells25. CD47 in
this context was proposed to prevent clearance of stem cells by NK
cells or macrophages expressing the CD47 counter-receptor
SIRPa16,25, but we propose that such stem cells must adapt to the
cell-autonomous inhibitory effects of high CD47 expression that
suppress c-Myc and other stem cell transcription factors. Myc
expression is presumably maintained through other regulatory path-
ways to preserve viability. The loss of viability that we observe fol-
lowing the acute withdrawal of c-Myc due to CD47-ligation or
restoring CD47 expression in null cells may be an example of
oncogene addiction in normal cells. These results indicate that a
downward excursion of Myc must be carefully managed to prevent
cell death or senescence.
Previous studies have implicated thrombospondin-1 as an inhib-
itor of certain stem cell functions but have not invoked CD47 as the
relevant receptor. Thrombospondin-1 null mice exhibited 5-fold
more circulating endothelial lineage-committed stem cells (EPCs,
CD131/VEGFR-21/CD452/CD1171) than WT mice60. Because the
elevation in EPCs was suppressed when the null mice were treated
with a drug targeting the thrombospondin receptor CD36, the
increased number of EPCs was attributed to loss of anti-angiogenic
thrombospondin-1 signaling via CD36 in the null. Conversely, ele-
vated thrombospondin-1 levels in diabetes and peripheral artery
disease have been associated with suppression of vascular wound
repair mediated by EPCs59,61. Notably, EPCs highly express CD47,
and suppression of CD47 by RNAi enhanced their proliferation and
angiogenic potential59. The authors attributed this to increased activ-
ity of the SDF-1/CXCR4 pathway, but the present data reveal a novel
and much broader role of CD47 to limit stem cell function by
suppressing c-Myc and other stem cell transcription factors.
Furthermore, because CD47 null stem cells show an enhanced capa-
city to differentiate along diverse lineages, we argue that the inhib-
itory function of CD47 in stem cell maintenance is not restricted to
the endothelial lineage.
These findings add new significance to the previously reported
inhibition of thrombospondin-1 transcription and mRNA stability
Figure 7 | Regulation of c-Myc and stem cell transcription factors byCD47 ligation. (A) c-MycmRNA in Jurkat (JK) andCD47-deficient JinB8 Jurkat T
cells (JIN). (B) Time-dependence for regulation of c-MycmRNA expression by theCD47 ligand thrombospondin-1. Jurkat cells were treated with 2.2 nM
thrombospondin-1 for the indicated times before isolating RNA and assessing c-Myc mRNA by real time PCR normalized to b2mmRNA and expressed
as a ratio to normalized c-Myc levels in control cells at the corresponding time points. (C) Thrombospondin-1 effects on c-MycmRNA inWT Jurkat and
CD47-deficient (JinB8) T lymphoma cells. (D) CD47 re-expression in JinB8 cells alters expression c-Myc compared with WT Jurkat cells. (E) Effects of
CD47-binding TSP1 peptide 7N3 and control peptide 604 on c-Myc mRNA expression in Jurkat T cells. (F and G) mRNA levels in thrombospondin-1-
null vs. WT lung and spleen. (H) CD47 over-expression in Rat1 fibroblasts and B16 melanoma cells does not suppress growth. (I) Deregulation of
translocated c-Myc in Raji Burkitt’s lymphoma cells prevents growth regulation by CD47 over-expression. (*p , 0.05, **p , 0.01).
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by elevated expression of c-Myc62,63. Combined with our results,
thrombospondin-1 and c-Myc can be seen to form a negative feed-
back loop in normal cells that limits the expression of both genes.
This feedback would normally limit the expression of inhibitory
thrombospondin-1 and thereby promote tissue renewal and regen-
eration. This feedback regulation is disrupted in Burkitt’s lymphoma
where transcriptional control of Myc expression by thrombospon-
din-1 is lost. Thus, c-Myc dysregulation may allow tumor cells to
maintain the elevated surface expression of CD47 that was first iden-
tified in ovarian carcinoma64 and subsequently extended to other
cancers3,17,18,21,25. Conversely, aging and chronic diseases such as
diabetes and pulmonary hypertension where thrombospondin-1
expression is elevated should limit c-Myc expression65–67, which
could contribute to pathogenesis of these diseases by limiting tissue
stem cell maintenance and function.
As an inhibitory cell surface receptor that controls self-renewal,
CD47 may be critical for understanding how the microenvironment
in the stem cell niche regulates stem cell differentiation68. CD47 may
directly transmit a negative signal from the environment that inhibits
self-renewal or proliferation, or lateral cross talk of CD47 with integ-
rins and growth factor receptors in the plasma membrane3,69 may
negatively modulate these signals in stem cells. Our studies identify
thrombospondin-1 as a key environmental signal that inhibits stem
cell self-renewal via CD47.
Methods
Animals. Thrombospondin-1 null70 CD47 null mice71 extensively back-crossed onto
a C57Bl/6J background and WT mice were housed in a specific pathogen-free
environment and had ad libitum access to standard rat chow and water. Care and
handling of animals and all experimental procedures used here were approved under
protocol LP-012 and in compliance with standards established by the Animal Care
and Use Committee of the National Cancer Institute.
Cells.Mouse lung endothelial cells were isolated and their purity verified as described
previously50. These conditions were previously documented to reproducibly yield
.95% pure endothelial cells at passage 2 (CD311, smooth muscle actin2). Mouse
lung endothelial cells were cultured at 37uC with 5% CO2 using Endothelial Growth
Medium-2 (EGM2, Fisher Scientific). Cell populations from mouse spleens were
separated using Pan T cell Isolation, CD4(L3T4), CD8a(Ly-2) CD11b, and CD19
microbead kits (Miltenyi Biotech).
V6.5 mouse embryonic stem (ES) cells were cultured on gelatin-coated dishes with
mouse embryonic fibroblast (MEF) feeder cells using standard mES medium
containing DMEM (high glucose), 15% ES cell-qualified FBS, 200 mM L-glutamine,
non-essential amino acids (LifeTechnology), Pen/Strep, 0.1 mM 2-mercaptoethanol,
and 1000 unit/ml LIF.
Western blots. Equal numbers of lung endothelial cells fromWT andCD47 null were
plated in 6-well plates overnight. Cell lysates were made from washed cells using NP-
40 lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl and 1% NP-40 along with
ProteoBlock Protease inhibitor Cocktail (Fermentas)). The lysates were centrifuged,
and equal volumes of supernatant were boiled with 43 NuPAGE–LDS sample buffer
(Invitrogen) for 5 min at 95uC. Proteins were separated using 4–12% Bis-Tris gels
(Invitrogen). N-terminal c-Myc antibody (Epitomics), human CD47 -B6H12, V5-
peroxidase (Invitrogen) and b-actin (Sigma) were used at 151000 to perform western
blots. Secondary anti-rabbit IgG or anti-mouse IgG conjugated to HRP were used at
155000. Super Signal West Pico chemiluminescent substrate (Fisher Scientific) was
used to detect bound antibodies. For protein normalization, the blots were reprobed
using a b-actin antibody (Sigma Aldrich).
Sox2 immunohistochemistry. Lung and spleen tissues from groups of 3 WT and
CD472/2mice were fixed in 10% formalin. Tissue was paraffin embedded and 5 mm
thick sections were immunostained using a Sox2 antibody (15100) or a non-specific
control antibody and detected using the DAKO LASB Universal Kit. Stained sections
were visualized and photographed under light microscope using the Q-Imaging
system.
Transient CD47 re- or over-expression. Isolated mouse lung endothelial cells, Raji
Burkitt’s lymphoma cells, B16melanoma cells, andMyc null Rat1 fibroblast cells were
plated overnight in 6-well plates. The cells were transfected with CD47-FLAG
expression plasmid72 and/or human c-Myc-GFP plasmid26. The cells were transfected
using Opti-MEMH I Reduced Serum Medium (Invitrogen) and the FuGENE HD
Transfection kit (Roche). The serum free medium was replaced with complete RPMI
medium 5 h after transfection. The cells were analyzed at 24–36 h post transfection.
The supernatants were analyzed for lactate dehydrogenase (LDH) release using
CytoTox 96H Non-Radioactive Cytotoxicity Assay (Promega).
The JINB8 cells were transfected with CD47-V5 construct using Amaxa (Lonza).
The transfection efficiency was determined by flow Cytometry. The CD47-V5
transfected cells were purified using magnetic beads preincubated with human CD47
antibody (B6H12). The transfected cells were loaded onto MACS column which was
placed in the magnetic field of a MACS separator. The magnetic bead labeled CD471
cells were retained on the column. The unbound cells were depleted from CD471
cells. After removal of the column, the CD471 cells bound to magnetic beads were
eluted. The Pure population of CD471 was stably cultured using G418 drug (250 ug/
ml). The Pure population of CD471 and Jurkat cells were centrifuged and re-sus-
pended in RPMI 1 1% FBS at 106/ml. Cells were plated in 12 well plates and treated
with 1 mg/ml (2.2 nM) thrombospondin-1, and total RNAwas isolated using TRIzol.
The relative gene expression of c-MYC was measured using GAPDH as a control.
CD47 knockdown in T cells and in WT mice. A translation-blocking antisense
morpholino oligonucleotide complementary to human and murine CD47 (CGTCA
CAGGCAGGACCCACTGCCCA) and a 5-base mismatch control morpholino
(CGTgACAGcCAcGACCgACTGCgCA) were obtained from GeneTools as
previously described48. Primary T cells isolated from c-Myc EGFP knock-in mouse
were transfected using morpholinos (2.5 mM) along with Endoporter according to
manufacturer’s instructions. Mice were treated by injection of 750 ml of 10 mM
morpholino in saline as described8. Organs were harvested for mRNA isolation after
48 h.
Modulation of stem cell transcription factors by thrombospondin-1. Jurkat and
JinB8 cells were centrifuged and re-suspended in RPMI 1 1% FBS at 106/ml. Cells
were plated in 12 well plates and treated with 1 mg/ml (2.2 nM) thrombospondin-1
using the indicated times and concentrations, and total RNA was isolated using
TRIzol.
Cell proliferation assays. Equal numbers of mouse lung endothelial cells from WT
and CD47 (Passage 1) were plated in 96 well plates using RPM111% FBS. After 72 h,
net cell proliferation was assessed by the increase in formazan absorbance versus
controls assessed at time 0 using Cell Titer 96R aqueous MTS kit (Promega). DNA
synthesis was measured using a BrdU Assay (EMD Biosciences).
Senescence-associated b-galactosidase assay. Senescent cells were detected in WT
and CD47 null lung endothelial cells (Passage 3) by staining for a senescence-
associated b-galactosidase73. Positive cell numbers were expressed as a percentage of
the total cells.
Statistical analysis. Two-way ANOVA with replication was used for analyzing real
time PCR. Student t-test was used for cell proliferation, cell cytotoxicity and cell
senescence assays, which were performed in triplicate. All results are presented as
mean 6 SD.
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